Price movement over the last 24 hours
Agilent Technologies Inc vs Cardinal Health Inc — how do they compare? Agilent Technologies Inc trades at $128.33 (market cap $37.04B), while Cardinal Health Inc trades at $239.13 (market cap $56.14B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Cardinal Health Inc pays the higher dividend (0.85%). Which is the better fit depends on your goals.
| A | CAH | |
|---|---|---|
Market Cap | $37.04B | $56.14B |
Sector | Health | Health |
52-Week High | $157.20 | $239.71 |
52-Week Low | $110.24 | $146.04 |
Enterprise Value | $38.59B | $61.12B |
Dividend Yield | 0.78% | 0.85% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Cardinal Health (CAH) trades at $239.71, up 0.32% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats, including Q1 2026 EPS of $3.17 beating estimates of $2.79. Revenue reached $222.58B in 2025 with net income of $1.56B. Technical indicators are bullish, with the current price above key support levels. Analysts maintain a positive outlook with a consensus price target of $243.33.
CAH presents a compelling investment case driven by earnings growth and defensive healthcare distribution. However, risks include high debt levels, thin profit margins, and competitive pressures. The stock's valuation at a P/E of 36.26 may limit upside if growth moderates. Overall, the bullish analyst consensus and operational strength support a positive medium-term view.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →